America based Regeneron Pharmaceuticals Inc Shares Outstripped

Regeneron Pharmaceuticals Inc. shares inched 0.16% higher to $503.23 Tuesday. This proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.13% to 34,575.31 and the S&P 500 Index SPX falling 0.05% to 4,202.04.

Regeneron Pharmaceuticals Inc. closed $161.41 short of its 52-week high ($664.64), which the company achieved on July 20th. The stock outperformed some of its competitors Tuesday, as Johnson & Johnson JNJ fell 2.20% to $165.53, Novartis AG ADR NVS fell 0.29% to $88.12, and Amgen Inc. AMGN fell 1.83% to $233.58. The trading volume (606,804) of Regeneron Pharmaceuticals Inc remained 212,168 below its 50-day average volume of 818,972. This stock maintains the consecutive two days gain.

The company also announced that it has resumed enrollment in its monotherapy studies of pipeline candidate odronextamab, a CD20xCD3 bispecific antibody. The company resumed enrolling patients with follicular lymphoma and diffuse large B-cell lymphoma in the studies after the FDA agreed to lift the partial clinical trial hold for those patient cohorts.

The company reminded investors that in December 2020, America based Regeneron paused new enrollment of patients with B-cell non-Hodgkin lymphomas in studies as the FDA had put a partial clinical hold. The agency requested that the company amend the trial protocols to further reduce the incidence of ≥Grade 3 cytokine release syndrome during step-up dosing. The syndrome, which is caused by a large, rapid release of immune substances called cytokines, may occur after treatment with some types of cancer therapies and can sometimes be severe or fatal.